AL Amyloidosis Therapeutics Market Size, Growth & Forecast

Q: What is the Current Market Valuation?

The market is valued at US$ 2.25 billion in 2023. Read Report

Q: How was the Market’s Historical Performance?

The market rose at a 5.2% CAGR from 2018 to 2022. Read Report

Q: What is the Expected Market Size in 2033?

The market is expected to reach US$ 4.56 billion by 2033. Read Report

Request Methodology

Global AL Amyloidosis Therapeutics Market Snapshot (2023 to 2033)

The global AL amyloidosis therapeutics market is slated to reach a valuation of US$ 2.25 billion by the end of 2023. According to Future Market Insights, the market is projected to rise at a 7.3% CAGR until 2033, being valued at US$ 4.56 billion.

The most common kind of systemic amyloidosis is the amyloid light chain (AL) amyloidosis, sometimes referred to as primary amyloidosis. Systemic light-chain (AL) amyloidosis was once thought to be an unstoppable deadly condition. The AL amyloidosis outlook was dismal prior to effective therapy for the fundamental plasma cell dyscrasia, with an average AL amyloidosis life expectancy of almost 13 months and to just 6 months for individuals with symptomatic cardiac dysfunction. Indicators of myocardial cell destruction and heart failure, that are exceedingly sensitive to cardiac dysfunction in amyloidosis, are the main focus of present AL amyloidosis staging techniques.

The purpose of AL amyloidosis therapy is to quickly decrease the plasma cell clone in order to increase amyloid reabsorption as well as restore organ function, hence enhancing patients' QOL, heart function, and survival. In the right patients, chemotherapy (both low and high dose) combined with autologous hematopoietic stem cell transplantation (ASCT) significantly lowers the formation of amyloid light chains. Melphalan, bortezomib and dexamethasone-based regimens should be used to treat patients who are ineligible for ASCT.

As one AL amyloidosis therapeutic approach, the National Comprehensive Cancer Network suggests high-dose melphalan followed by ASCT. Treatment for AL amyloidosis is very customized and should be focused on hematologic as well as cardiac response indicators as well as organ dysfunction, age, and regimen toxicity. Alkylator-based chemotherapy is beneficial for around two thirds of patients. Also, there are tests being conducted to determine the optimum way to use novel agents. Such developments are expected to people the demand in the market from 2023 to 2033.

Data Points	Key Statistics
Anticipated Base Year Value (2022)	US$ 2.1 billion
Expected Market Value (2023)	US$ 2.25 billion
Projected Forecast Value (2033)	US$ 4.56 billion
Global Growth Rate (2023 to 2033)	7.3%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 To 2022 AL Amyloidosis Therapeutics Market Demand Analysis Vs. Forecast 2023 To 2033

The global AL amyloidosis therapeutics market grew at a CAGR of 5.2% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence. Although this condition is more common in adults above the age of 60 years and older, the growing geriatric population in both developed and emerging nations is also driving the demand in the global AL amyloidosis therapeutics market.

Also, the market for AL amyloidosis treatments is accelerating due to increased governmental and private sector funding, research, and development efforts. The development of healthcare technology and growing public awareness of rare illnesses are expected to support market expansion in the years to come. As a result, the global AL amyloidosis therapeutics market is expected to forecast a CAGR over 8% from 2023 to 2033.

Prominent Growth Drivers Influencing AL Amyloidosis Therapeutics Market

Various biological advancements used in this therapy is driving the market expansion

The market for AL amyloidosis therapeutics is largely being driven by the rise in incidences of mutations in blood cell DNA and the prevalence of underlying plasma cell illnesses such as monoclonal gammopathy and multiple myeloma of uncertain significance.

Also, the widespread use of amyloid stabilizers, which stabilize the amyloid protein and stop it from building up in tissues and organs, is supporting the market's expansion. Moreover, the increasing use of innovative treatments that target the underlying causes of AL amyloidosis, such as immunomodulatory medications, proteasome inhibitors, monoclonal antibodies, etc. has considerably increased patient response times and lengthened progression-free life. This in turn is serving as yet another important component that promotes development.

The market is also expanding owing to the rising demand for high-dose chemotherapy, accompanied by autologous transplantation of stem cells, as a therapeutic option for patients admitted with AL amyloidosis. This therapy tries to enhance organ function by removing aberrant cells that generate amyloid protein. Moreover, continual improvements in diagnostic methods, such as the development of serum-free light chain tests as well as mass spectrometry, have made it possible to make diagnoses sooner, enabling quicker treatment to begin and improved control of disease-related problems. Hence, the market for AL amyloidosis therapeutics is anticipated to grow throughout the course of the projected period.

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What Could Possibly Hinder AL Amyloidosis Therapeutics Market Demand?

Lack of information and clinical studies is expected to impede the market growth

There is a shortage of epidemiological information on AL amyloidosis, and retrospective analysis reduces the validity of the data, which limits the market's potential growth. Additionally, the complex heterogeneity of the illnesses delays diagnosis, leading to severe disease (organ malfunction, including kidney, heart, and liver), lowering survival rates for AL amyloidosis, and acting as a roadblock to the expansion of the AL amyloidosis therapeutics market.

Clinical studies for AL amyloidosis therapeutics are also difficult to conduct successfully because of low patient recruitment as well as a lack of strictly delineated new outcomes. The participation of the kidney and heart systems results in expensive medical care. Moreover, the anticipated releases will probably cost more than myeloma-based medications, which may limit the accessibility and affordability of the AL amyloidosis therapies. Additionally, the function of upfront ASCT in various eligible patients has to be addressed in the era of daratumumab-based therapy. The aforementioned issues thus restrict the growth of the AL amyloidosis therapeutics market.

Region-wise Analysis

What Is the Outlook of the North American AL Amyloidosis Therapeutics Market?

Rising incidence of amyloidosis cases along with innovative products will boost the growth

During the forecast period, the North American market for AL amyloidosis therapeutics is expected to be the most volatile one. As per Future Market Insights, this region is expected to proliferate with a robust CAGR of 7.9% from 2023 to 2033.

The adoption of innovative therapies surged as a result of the prospective release of pipeline medications, and its dominating market share is also largely due to the high expense of healthcare in the United States. Around 3,900 new instances of AL amyloidosis are detected each year in the United States, making it the most prevalent kind.

This disease variant's diagnostic age is often in the mid-60s. Its yearly incidence in North American nations is roughly 15 instances per million persons, or about one-fifth that of myeloma, a blood cancer brought on by clonal plasma cells found in the bone marrow. Moreover, it can be challenging to diagnose since symptoms including weariness, paresthesia, edema, and weight loss frequently coexist with those of other prevalent illnesses. Hence, during the forecast period, the North American region can be expected to show a significant growth rate, acquiring a global market share of 39% in the year 2023.

What can Be expected from the Asia Pacific Market for AL Amyloidosis Therapeutics?

Enhanced healthcare facilities and strong patient pool to accelerate growth

During the forecast period, the Asia Pacific market for AL amyloidosis therapeutics is expected to garner a steady CAGR of 7.6%. The Asia Pacific AL amyloidosis therapeutics market is anticipated to grow quickly throughout the time of forecasting. This is because two of the three late-stage medications have received approval in Asia Pacific to treat amyloidosis. Due to supportive government policies, enhanced healthcare infrastructure, and greater investment, emerging markets for amyloidosis, such as China and India, are anticipated to have enticing development throughout the projection period.

The strong need for economical healthcare in these nations with big populations and low per capita incomes will fuel the growth of chemotherapy generic versions in this market. Alternatives for curative treatments with increased effectiveness are desperately needed. Hence, factors such as these are expected to accelerate the growth in the regional market from 2023 to 2033.

Category-wise Insights

Which treatment segment is expected to gain traction from 2023 to 2033?

The chemotherapy segment will gain the dominant market share

Over the course of the forecast period, the chemotherapy segment by treatment type is anticipated to occupy a significant share of the global AL amyloidosis therapeutics market. In 2023, this category is anticipated to dominate with a 53% revenue share.

Anti-cancer treatments or chemotherapy are used to treat AL amyloidosis because they slow the proliferation of the aberrant cells that produce amyloid. Such factors are expected to accelerate the growth prospects for AL amyloidosis therapeutics from 2023 to 2033.

Which Distribution Channel is expected to gain traction during 2023 to 2033?

Hospital pharmacies segment will demand during the forecast period

Future Market Insights' study indicates that the hospital pharmacy segment would expand throughout the projected period. From 2023 to 2033, it is predicted that this market segment would have a 25% share of the global market.

Patients who are diagnosed with AL amyloidosis are mostly being treated in the hospitals under the supervision of the specialized doctors. With such patients, no doctor takes the risk of the treating them at home. Hence, as the treatment is being conducted in the hospitals itself, most of the medications and therapies are provided by the hospitals.

Start-up Scenario

The start-ups in this sector aim to use a number of techniques, such as the launch of new products and acquisitions, to improve their market positions internationally.

Attralus Therapeutics received $116 million in 2021 to launch a few amyloidosis treatments and a companion radiotracer diagnostic agent. This novel biotechnology is centered on treatments that amplify the immune system's capacity to eliminate amyloid. Amyloid disorders are a group of serious, frequently deadly ailments caused by an accumulation of the amyloid protein in essential tissues and organs.

How Competitive is the Market for AL amyloidosis therapeutics?

The launch of Darzalex Faspro by Genmab as well as Janssen Biotech, as well as AstraZeneca's purchase of Caelum Biosciences in 2021, are two examples of how significant industry players are increasing their understanding of the disease and working together. One of the main drivers of the AL amyloidosis therapeutics market growth is the strong pipeline with innovative, first-in-class medicines for the treatment of the disease.

Some of the important developments of the key players of the market are

A collaboration to explore CAEL-101 for light chain (AL) amyloidosis was announced in 2019 by Alexion Pharmaceuticals, Inc. and Caelum Biosciences. First-in-class and an amyloid fibril targeted treatment CAEL-101 is intended to enhance organ function in individuals with AL amyloidosis by decreasing or removing amyloid deposits. They think CAEL-101 has a great deal of potential to benefit these patients, and they're thrilled to include it in their expanding pipeline of rare hematological clinical-stage drugs.
Janssen Biotech disclosed in January 2021 that the Food and Drug Administration approved daratumumab with hyaluronidase in conjunction with bortezomib, dexamethasone and cyclophosphamide for recently diagnosed light chain (AL) amyloidosis. The Phase III ANDROMEDA study, which is testing daratumumab as well as hyaluronidase for the diagnosis of individuals who have newly diagnosed light chain (AL) amyloidosis, a rare blood cell disorder linked to the decline of vital organs, most noticeably the kidneys, heart, and liver, recently reported updated positive results.

Some of the prominent players in the global market for AL amyloidosis therapeutics are

Janssen Pharmaceutical
Prothena
Alexion Pharmaceuticals
Oncopeptides AB
Bristol-Myers Squibb
GlaxoSmithKline Pharmaceuticals Ltd
Celgene Corp
Eidos Therapeutics, Inc.
Corino Therapeutics, Inc.
Spectrum Pharmaceuticals, Inc.
Pfizer

Report Scope

Report Attribute	Details
Growth Rate	CAGR of 7.3% from 2023 to 2033
Market value in 2023	US$ 2.25 billion
Market value in 2033	US$ 4.56 billion
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	US$ Billion for Value and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered	Treatment Drug Distribution Channel Region
Regions Covered	North America Latin America Europe Asia Pacific Middle East & Africa
Key Countries Profiled	United States Canada Brazil Mexico United Kingdom Spain Germany Italy France Rest of Europe China Japan South Korea India South Africa GCC Countries
Key Companies Profiled	Janssen Pharmaceutical Prothena Alexion Pharmaceuticals Oncopeptides AB Bristol-Myers Squibb GlaxoSmithKline Pharmaceuticals Ltd Celgene Corp Eidos Therapeutics, Inc. Corino Therapeutics, Inc. Spectrum Pharmaceuticals, Inc. Pfizer
Customization Scope	Available on Request

Key Segments Covered in the AL amyloidosis therapeutics market Report

By Treatment:

Chemotherapy
Supportive Care
Surgery
Stem Cell Transplant
Targeted Therapy

By Drugs:

Transthyretin Transport Inhibitor
Immunomodulatory Drugs
Monoclonal Antibodies
Proteasome Inhibitors
Others

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region:

North America
Latin America
Europe
Asia Pacific
Middle East & Africa

Frequently Asked Questions

What is the Current Market Valuation?

The market is valued at US$ 2.25 billion in 2023.

How was the Market’s Historical Performance?

The market rose at a 5.2% CAGR from 2018 to 2022.

What is the Growth Forecast for the AL Amyloidosis Therapeutics Market?

The market is forecast to secure a CAGR of 7.3% through 2033.

What is the Expected Market Size in 2033?

The market is expected to reach US$ 4.56 billion by 2033.

What is North America's Projected CAGR until 2033?

North America is expected to accumulate a CAGR of 7.9% until 2033.

Table of Content

1. Executive Summary | AL Amyloidosis Therapeutics Market

1.1. Global Market Outlook

1.2. Demand-side Trends

1.3. Supply-side Trends

1.4. Technology Roadmap Analysis

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Market Background

3.1. Market Dynamics

3.1.1. Drivers

3.1.2. Restraints

3.1.3. Opportunity

3.1.4. Trends

3.2. Scenario Forecast

3.2.1. Demand in Optimistic Scenario

3.2.2. Demand in Likely Scenario

3.2.3. Demand in Conservative Scenario

3.3. Opportunity Map Analysis

3.4. Investment Feasibility Matrix

3.5. PESTLE and Porter’s Analysis

3.6. Regulatory Landscape

3.6.1. By Key Regions

3.6.2. By Key Countries

3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

4.2.1. Y-o-Y Growth Trend Analysis

4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment

5.1. Introduction / Key Findings

5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022

5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033

5.3.1. Chemotherapy

5.3.2. Supportive Care

5.3.3. Surgery

5.3.4. Stem Cell Transplant

5.3.5. Targeted Therapy

5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022

5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drugs

6.1. Introduction / Key Findings

6.2. Historical Market Size Value (US$ Million) Analysis By Drugs, 2018 to 2022

6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drugs, 2023 to 2033

6.3.1. Transthyretin Transport Inhibitor

6.3.2. Immunomodulatory Drugs

6.3.3. Monoclonal Antibodies

6.3.4. Proteasome Inhibitors

6.3.5. Others

6.4. Y-o-Y Growth Trend Analysis By Drugs, 2018 to 2022

6.5. Absolute $ Opportunity Analysis By Drugs, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

7.1. Introduction / Key Findings

7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2018 to 2022

7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033

7.3.1. Hospital Pharmacies

7.3.2. Retail Pharmacies

7.3.3. Online Pharmacies

7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018 to 2022

7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

8.1. Introduction

8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

8.3.1. North America

8.3.2. Latin America

8.3.3. Europe

8.3.4. Asia Pacific

8.3.5. Middle East and Africa

8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

9.2.1. By Country

9.2.1.1. USA

9.2.1.2. Canada

9.2.2. By Treatment

9.2.3. By Drugs

9.2.4. By Distribution Channel

9.3. Market Attractiveness Analysis

9.3.1. By Country

9.3.2. By Treatment

9.3.3. By Drugs

9.3.4. By Distribution Channel

9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

10.2.1. By Country

10.2.1.1. Brazil

10.2.1.2. Mexico

10.2.1.3. Rest of Latin America

10.2.2. By Treatment

10.2.3. By Drugs

10.2.4. By Distribution Channel

10.3. Market Attractiveness Analysis

10.3.1. By Country

10.3.2. By Treatment

10.3.3. By Drugs

10.3.4. By Distribution Channel

10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

11.2.1. By Country

11.2.1.1. United kingdom

11.2.1.2. Spain

11.2.1.3. Germany

11.2.1.4. Italy

11.2.1.5. France

11.2.1.6. Rest of Europe

11.2.2. By Treatment

11.2.3. By Drugs

11.2.4. By Distribution Channel

11.3. Market Attractiveness Analysis

11.3.1. By Country

11.3.2. By Treatment

11.3.3. By Drugs

11.3.4. By Distribution Channel

11.4. Key Takeaways

12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

12.2.1. By Country

12.2.1.1. China

12.2.1.2. Japan

12.2.1.3. India

12.2.1.4. South Korea

12.2.1.5. Rest of Asia Pacific

12.2.2. By Treatment

12.2.3. By Drugs

12.2.4. By Distribution Channel

12.3. Market Attractiveness Analysis

12.3.1. By Country

12.3.2. By Treatment

12.3.3. By Drugs

12.3.4. By Distribution Channel

12.4. Key Takeaways

13. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

13.2.1. By Country

13.2.1.1. South Africa

13.2.1.2. GCC Countries

13.2.1.3. Rest of Middle East and Africa

13.2.2. By Treatment

13.2.3. By Drugs

13.2.4. By Distribution Channel

13.3. Market Attractiveness Analysis

13.3.1. By Country

13.3.2. By Treatment

13.3.3. By Drugs

13.3.4. By Distribution Channel

13.4. Key Takeaways

14. Key Countries Market Analysis

14.1. USA

14.1.1. Pricing Analysis

14.1.2. Market Share Analysis, 2022

14.1.2.1. By Treatment

14.1.2.2. By Drugs

14.1.2.3. By Distribution Channel

14.2. Canada

14.2.1. Pricing Analysis

14.2.2. Market Share Analysis, 2022

14.2.2.1. By Treatment

14.2.2.2. By Drugs

14.2.2.3. By Distribution Channel

14.3. Brazil

14.3.1. Pricing Analysis

14.3.2. Market Share Analysis, 2022

14.3.2.1. By Treatment

14.3.2.2. By Drugs

14.3.2.3. By Distribution Channel

14.4. Mexico

14.4.1. Pricing Analysis

14.4.2. Market Share Analysis, 2022

14.4.2.1. By Treatment

14.4.2.2. By Drugs

14.4.2.3. By Distribution Channel

14.5. United kingdom

14.5.1. Pricing Analysis

14.5.2. Market Share Analysis, 2022

14.5.2.1. By Treatment

14.5.2.2. By Drugs

14.5.2.3. By Distribution Channel

14.6. Spain

14.6.1. Pricing Analysis

14.6.2. Market Share Analysis, 2022

14.6.2.1. By Treatment

14.6.2.2. By Drugs

14.6.2.3. By Distribution Channel

14.7. Germany

14.7.1. Pricing Analysis

14.7.2. Market Share Analysis, 2022

14.7.2.1. By Treatment

14.7.2.2. By Drugs

14.7.2.3. By Distribution Channel

14.8. Italy

14.8.1. Pricing Analysis

14.8.2. Market Share Analysis, 2022

14.8.2.1. By Treatment

14.8.2.2. By Drugs

14.8.2.3. By Distribution Channel

14.9. France

14.9.1. Pricing Analysis

14.9.2. Market Share Analysis, 2022

14.9.2.1. By Treatment

14.9.2.2. By Drugs

14.9.2.3. By Distribution Channel

14.10. China

14.10.1. Pricing Analysis

14.10.2. Market Share Analysis, 2022

14.10.2.1. By Treatment

14.10.2.2. By Drugs

14.10.2.3. By Distribution Channel

14.11. Japan

14.11.1. Pricing Analysis

14.11.2. Market Share Analysis, 2022

14.11.2.1. By Treatment

14.11.2.2. By Drugs

14.11.2.3. By Distribution Channel

14.12. India

14.12.1. Pricing Analysis

14.12.2. Market Share Analysis, 2022

14.12.2.1. By Treatment

14.12.2.2. By Drugs

14.12.2.3. By Distribution Channel

14.13. South Korea

14.13.1. Pricing Analysis

14.13.2. Market Share Analysis, 2022

14.13.2.1. By Treatment

14.13.2.2. By Drugs

14.13.2.3. By Distribution Channel

14.14. South Africa

14.14.1. Pricing Analysis

14.14.2. Market Share Analysis, 2022

14.14.2.1. By Treatment

14.14.2.2. By Drugs

14.14.2.3. By Distribution Channel

14.15. GCC Countries

14.15.1. Pricing Analysis

14.15.2. Market Share Analysis, 2022

14.15.2.1. By Treatment

14.15.2.2. By Drugs

14.15.2.3. By Distribution Channel

15. Market Structure Analysis

15.1. Competition Dashboard

15.2. Competition Benchmarking

15.3. Market Share Analysis of Top Players

15.3.1. By Regional

15.3.2. By Treatment

15.3.3. By Drugs

15.3.4. By Distribution Channel

16. Competition Analysis

16.1. Competition Deep Dive

16.1.1. Janssen Pharmaceutical

16.1.1.1. Overview

16.1.1.2. Product Portfolio

16.1.1.3. Profitability by Market Segments

16.1.1.4. Sales Footprint

16.1.1.5. Strategy Overview

16.1.1.5.1. Marketing Strategy

16.1.2. Prothena

16.1.2.1. Overview

16.1.2.2. Product Portfolio

16.1.2.3. Profitability by Market Segments

16.1.2.4. Sales Footprint

16.1.2.5. Strategy Overview

16.1.2.5.1. Marketing Strategy

16.1.3. Alexion Pharmaceuticals

16.1.3.1. Overview

16.1.3.2. Product Portfolio

16.1.3.3. Profitability by Market Segments

16.1.3.4. Sales Footprint

16.1.3.5. Strategy Overview

16.1.3.5.1. Marketing Strategy

16.1.4. Oncopeptides AB

16.1.4.1. Overview

16.1.4.2. Product Portfolio

16.1.4.3. Profitability by Market Segments

16.1.4.4. Sales Footprint

16.1.4.5. Strategy Overview

16.1.4.5.1. Marketing Strategy

16.1.5. Bristol-Myers Squibb

16.1.5.1. Overview

16.1.5.2. Product Portfolio

16.1.5.3. Profitability by Market Segments

16.1.5.4. Sales Footprint

16.1.5.5. Strategy Overview

16.1.5.5.1. Marketing Strategy

16.1.6. GlaxoSmithKline Pharmaceuticals Ltd

16.1.6.1. Overview

16.1.6.2. Product Portfolio

16.1.6.3. Profitability by Market Segments

16.1.6.4. Sales Footprint

16.1.6.5. Strategy Overview

16.1.6.5.1. Marketing Strategy

16.1.7. Celgene Corp

16.1.7.1. Overview

16.1.7.2. Product Portfolio

16.1.7.3. Profitability by Market Segments

16.1.7.4. Sales Footprint

16.1.7.5. Strategy Overview

16.1.7.5.1. Marketing Strategy

16.1.8. Eidos Therapeutics, Inc.

16.1.8.1. Overview

16.1.8.2. Product Portfolio

16.1.8.3. Profitability by Market Segments

16.1.8.4. Sales Footprint

16.1.8.5. Strategy Overview

16.1.8.5.1. Marketing Strategy

16.1.9. Corino Therapeutics, Inc.

16.1.9.1. Overview

16.1.9.2. Product Portfolio

16.1.9.3. Profitability by Market Segments

16.1.9.4. Sales Footprint

16.1.9.5. Strategy Overview

16.1.9.5.1. Marketing Strategy

16.1.10. Spectrum Pharmaceuticals, Inc.

16.1.10.1. Overview

16.1.10.2. Product Portfolio

16.1.10.3. Profitability by Market Segments

16.1.10.4. Sales Footprint

16.1.10.5. Strategy Overview

16.1.10.5.1. Marketing Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Drugs, 2018 to 2033

Table 4: Global Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 7: North America Market Value (US$ Million) Forecast by Drugs, 2018 to 2033

Table 8: North America Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 10: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 11: Latin America Market Value (US$ Million) Forecast by Drugs, 2018 to 2033

Table 12: Latin America Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033

Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 15: Europe Market Value (US$ Million) Forecast by Drugs, 2018 to 2033

Table 16: Europe Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033

Table 17: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 18: Asia Pacific Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 19: Asia Pacific Market Value (US$ Million) Forecast by Drugs, 2018 to 2033

Table 20: Asia Pacific Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033

Table 21: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 22: Middle East and Africa Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 23: Middle East and Africa Market Value (US$ Million) Forecast by Drugs, 2018 to 2033

Table 24: Middle East and Africa Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033

List of Charts

Figure 1: Global Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Drugs, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Distribution Channel , 2023 to 2033

Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 8: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 9: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 10: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 11: Global Market Value (US$ Million) Analysis by Drugs, 2018 to 2033

Figure 12: Global Market Value Share (%) and BPS Analysis by Drugs, 2023 to 2033

Figure 13: Global Market Y-o-Y Growth (%) Projections by Drugs, 2023 to 2033

Figure 14: Global Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033

Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033

Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033

Figure 17: Global Market Attractiveness by Treatment, 2023 to 2033

Figure 18: Global Market Attractiveness by Drugs, 2023 to 2033

Figure 19: Global Market Attractiveness by Distribution Channel , 2023 to 2033

Figure 20: Global Market Attractiveness by Region, 2023 to 2033

Figure 21: North America Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 22: North America Market Value (US$ Million) by Drugs, 2023 to 2033

Figure 23: North America Market Value (US$ Million) by Distribution Channel , 2023 to 2033

Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 28: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 29: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 30: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 31: North America Market Value (US$ Million) Analysis by Drugs, 2018 to 2033

Figure 32: North America Market Value Share (%) and BPS Analysis by Drugs, 2023 to 2033

Figure 33: North America Market Y-o-Y Growth (%) Projections by Drugs, 2023 to 2033

Figure 34: North America Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033

Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033

Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033

Figure 37: North America Market Attractiveness by Treatment, 2023 to 2033

Figure 38: North America Market Attractiveness by Drugs, 2023 to 2033

Figure 39: North America Market Attractiveness by Distribution Channel , 2023 to 2033

Figure 40: North America Market Attractiveness by Country, 2023 to 2033

Figure 41: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 42: Latin America Market Value (US$ Million) by Drugs, 2023 to 2033

Figure 43: Latin America Market Value (US$ Million) by Distribution Channel , 2023 to 2033

Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 48: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 49: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 51: Latin America Market Value (US$ Million) Analysis by Drugs, 2018 to 2033

Figure 52: Latin America Market Value Share (%) and BPS Analysis by Drugs, 2023 to 2033

Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Drugs, 2023 to 2033

Figure 54: Latin America Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033

Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033

Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033

Figure 57: Latin America Market Attractiveness by Treatment, 2023 to 2033

Figure 58: Latin America Market Attractiveness by Drugs, 2023 to 2033

Figure 59: Latin America Market Attractiveness by Distribution Channel , 2023 to 2033

Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 61: Europe Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 62: Europe Market Value (US$ Million) by Drugs, 2023 to 2033

Figure 63: Europe Market Value (US$ Million) by Distribution Channel , 2023 to 2033

Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 68: Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 69: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 70: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 71: Europe Market Value (US$ Million) Analysis by Drugs, 2018 to 2033

Figure 72: Europe Market Value Share (%) and BPS Analysis by Drugs, 2023 to 2033

Figure 73: Europe Market Y-o-Y Growth (%) Projections by Drugs, 2023 to 2033

Figure 74: Europe Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033

Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033

Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033

Figure 77: Europe Market Attractiveness by Treatment, 2023 to 2033

Figure 78: Europe Market Attractiveness by Drugs, 2023 to 2033

Figure 79: Europe Market Attractiveness by Distribution Channel , 2023 to 2033

Figure 80: Europe Market Attractiveness by Country, 2023 to 2033

Figure 81: Asia Pacific Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 82: Asia Pacific Market Value (US$ Million) by Drugs, 2023 to 2033

Figure 83: Asia Pacific Market Value (US$ Million) by Distribution Channel , 2023 to 2033

Figure 84: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033

Figure 85: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 86: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 87: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 88: Asia Pacific Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 89: Asia Pacific Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 90: Asia Pacific Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 91: Asia Pacific Market Value (US$ Million) Analysis by Drugs, 2018 to 2033

Figure 92: Asia Pacific Market Value Share (%) and BPS Analysis by Drugs, 2023 to 2033

Figure 93: Asia Pacific Market Y-o-Y Growth (%) Projections by Drugs, 2023 to 2033

Figure 94: Asia Pacific Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033

Figure 95: Asia Pacific Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033

Figure 96: Asia Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033

Figure 97: Asia Pacific Market Attractiveness by Treatment, 2023 to 2033

Figure 98: Asia Pacific Market Attractiveness by Drugs, 2023 to 2033

Figure 99: Asia Pacific Market Attractiveness by Distribution Channel , 2023 to 2033

Figure 100: Asia Pacific Market Attractiveness by Country, 2023 to 2033

Figure 101: Middle East and Africa Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 102: Middle East and Africa Market Value (US$ Million) by Drugs, 2023 to 2033

Figure 103: Middle East and Africa Market Value (US$ Million) by Distribution Channel , 2023 to 2033

Figure 104: Middle East and Africa Market Value (US$ Million) by Country, 2023 to 2033

Figure 105: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 106: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 107: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 108: Middle East and Africa Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 109: Middle East and Africa Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 110: Middle East and Africa Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 111: Middle East and Africa Market Value (US$ Million) Analysis by Drugs, 2018 to 2033

Figure 112: Middle East and Africa Market Value Share (%) and BPS Analysis by Drugs, 2023 to 2033

Figure 113: Middle East and Africa Market Y-o-Y Growth (%) Projections by Drugs, 2023 to 2033

Figure 114: Middle East and Africa Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033

Figure 115: Middle East and Africa Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033

Figure 116: Middle East and Africa Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033

Figure 117: Middle East and Africa Market Attractiveness by Treatment, 2023 to 2033

Figure 118: Middle East and Africa Market Attractiveness by Drugs, 2023 to 2033

Figure 119: Middle East and Africa Market Attractiveness by Distribution Channel , 2023 to 2033

Figure 120: Middle East and Africa Market Attractiveness by Country, 2023 to 2033

March 2023

REP-GB-16805

303 pages

Healthcare

Sabyasachi Ghosh

Book Now

Clients

Customize This Research

Quick Contact

Chat on Whatsapp + 44 (0) 20 3287 4268 + 44 (0) 20 8123 9659 + 1 347 918 3531 Contact By Email

- Trust FMI -

- Member of -

Greater New York Chamber of Commerce

- Awarded by -

BRONZE STEVIE® Award

20th annual IBAs

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

- Recognized by -

AL Amyloidosis Therapeutics Market

Market Survey on AL Amyloidosis Therapeutics Market Covering Sales Outlook, Up-to-date Key Trends, Market Size and Forecast, Per Capita Expenditure, Company Share, Brand Share, Regulations, Reimbursement Scenario, Epidemiology, Procedure Numbers, and Pipeline Assessment